Oncolytics Biotech Takes Center Stage at Investment Conferences
Oncolytics Biotech Inc. (NASDAQ: ONCY), a prominent clinical-stage biotechnology firm, has announced its participation in key investment conferences aimed at highlighting advancements in cancer immunotherapy. The company is committed to pioneering innovative treatments and continues to play a crucial role in the battle against various cancer types.
Fireside Chats Scheduled with Key Leaders
Kirk Look, the Chief Financial Officer, is set to participate in an engaging fireside chat at the well-regarded H.C. Wainwright 26th Annual Global Investment Conference. This event will take place at the Lotte New York Palace Hotel and will serve as a valuable platform for discussing Oncolytics' strategic initiatives in oncology.
Details of the H.C. Wainwright Conference
The conference is scheduled for September 11, with Kirk Look's presentation slated for 9:00 a.m. ET. Attendees can look forward to gaining in-depth insights into Oncolytics’ direction and performance in the immuno-oncology arena.
Participation at the Cantor Global Healthcare Conference
Additionally, Oncolytics' Chief Medical Officer, Tom Heineman, M.D., Ph.D., will be sharing his expertise during a fireside chat at the Cantor 2024 Global Healthcare Conference on September 19. This session will provide investors and stakeholders with valuable insights into the therapeutic potential of pelareorep, Oncolytics’ groundbreaking immunotherapeutic agent.
Highlights of the Cantor Conference
Tom Heineman is scheduled to present at 10:55 a.m. ET at the InterContinental New York Barclay Hotel, focusing on how pelareorep is revolutionizing treatment methods in oncology.
One-on-One Investor Meetings to Enhance Engagement
Alongside group discussions, the management team will facilitate one-on-one meetings with investors throughout the conferences. Stakeholders are encouraged to request these meetings via the conference platforms or by contacting their respective representatives directly.
About Pelareorep and Oncolytics’ Clinical Trials
Oncolytics Biotech is leading the development of pelareorep, an intravenously administered agent that has demonstrated significant promise in treating metastatic breast cancer and pancreatic cancer. By stimulating immune system responses, pelareorep uniquely transforms “cold” tumors into “hot” tumors, making them more responsive to various cancer therapies.
Current clinical trials suggest that pelareorep can enhance the effectiveness of existing oncology treatments. Oncolytics is making diligent progress towards registrational studies for both metastatic breast cancer and pancreatic cancer, which have received Fast Track designation from the FDA. This designation highlights the urgency and potential impact of their research findings.
Connect with Oncolytics Biotech
For more information about Oncolytics Biotech Inc. and its innovative approaches in oncology, visit their official website or follow their updates on social media platforms.
Frequently Asked Questions
What is Oncolytics Biotech known for?
Oncolytics Biotech Inc. is recognized for its innovative immunotherapeutic agent, pelareorep, which is being developed to treat various cancer types.
When are the upcoming investment conferences?
The H.C. Wainwright Annual Conference is set for September 11, and the Cantor Global Healthcare Conference will occur on September 19.
Who will represent Oncolytics at the conferences?
Kirk Look and Tom Heineman will represent Oncolytics during their respective fireside chats at the conferences.
How can investors schedule one-on-one meetings?
Investors can arrange one-on-one meetings through the conference websites or by reaching out to their representatives.
What advancements has pelareorep shown in clinical trials?
Pelareorep has demonstrated promising results in triggering anti-cancer immune responses and improving treatment effectiveness for metastatic breast cancer and pancreatic cancer.